Reply
Sir, We read with interest the article by Lionaki et al. on thyroid disease and vasculitis [1] . We would like to take issue with their conclusion that 'the association [of vasculitis] with thyroid disease was not driven by use of anti-thyroid agents and these agents are unlikely to account for many cases in the general population' [1] . ANCA positivity as well as clinical and/or histological evidence of vasculitis in conjunction with anti-thyroid medication has been described repeatedly, and propylthiouracil (PTU) has been implicated in the majority of cases. A current PubMed query for 'anti-thyroid' and 'vasculitis' yields as many as 106 papers on this subject. In 2000, Gunton et al. reported ANCA positivity in 26.7% of patients in a small cohort of patients of anti-thyroid drugs [2] , and listed 32 cases of vasculitis in association with anti-thyroid drugs from the literature [2] . In a more recent cross-sectional study of ANCA development in 607 patients with thyroid disease, ANCA positivity was observed in 33.3% of PTUtreated patients, 15.9% of carbimazole-treated patients but only 3.8% of thionamide-naïve patients [3] . In another recent study, Slot et al. from the Netherlands detected ANCA in 6% of 207 patients with hyperthyroidism; they also observed a strong association with anti-thyroid drugs (odds ratio 11.8) [4] . Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis induced by PTU has been demonstrated in cats by Waldhauser and Uetrecht, and the same authors reported that PTU is oxidized in the presence of myeloperoxidase (MPO) to form reactive intermediates [5] . The latter observation may offer a clue as to the pathogenesis of vasculitis after thionamide exposure.
In their study, Lionaki et al. relied mainly on telephone interviews to ascertain the presence of thyroid disease and anti-thyroid medication. Medical charts were available in only 52% of patients, and a proxy interview had to be conducted for 29 patients. We very much appreciate the work by Lionaki et al. [1] and believe that their data show an association of vasculitis and thyroid disease. However, we doubt whether their methodology is sufficient to question the apparently well-documented association between anti-thyroid drugs and vasculitis. Clinical experience indicates that patients and relatives often forget or confuse medication. This may be particularly true when the disease or treatment in question occurred years ago. Intriguingly, Slot et al.'s data suggest that ANCA positivity and vasculitis may occur years after treatment with thionamides [4] . Finally, Lionaki and colleagues report use of anti-thyroid drugs in only 2 out of 31 patients (6.45%) who recalled thyroid disease. The expected ratio of thionamide exposure in Lionaki's study population is difficult to gauge, but we think it is rather unlikely that so few patients in their study were truly thionamide naïve. Figure, that the results DO NOT refer to patients who actually receive dialysis but rather to patients who elect to receive dialysis. The authors are careful to point this out within the article itself but the more 'casual' reader should be warned that the survival curves and hazard ratios shown in the article do not reflect the actual treatment received during the course of follow-up. Indeed, an analysis reflecting the actual treatment received would require using a more sophisticated Cox-proportional hazards model with time-dependent treatment groups. Such an as-treated analysis may or may not alter the conclusions reached from the authors' intent-to-treat analysis. For example, the total number of deaths attributed to the dialysis group is mentioned as 12. However, as noted by the authors, 8 of 12 died prior to starting dialysis. Another 16 in the dialysis group never started dialysis prior to the study completion date. How were these 24 patients managed? We presume that they were given the same treatment that was offered to patients in the conservative arm before starting dialysis. In an as-treated type of analysis, the total number of patients who actually received dialysis would be 52 − 24 = 28, out of which 4 would have died following the initiation of dialysis. Likewise, at initiation, the conservative treatment arm would have started off with a total of 77 + 24 = 101 patients, of which 59 (=51 + 8) would have died while on conservative treatment. Thus, an as-treated analysis may or may not yield results and/or conclusions different from those reached by the authors. It is not that we object to the intent-to-treat approach taken by the authors, it is just that results could vary according to the type of analysis one performs and we wish to make readers aware of such a possibility.
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Sir, We agree that the result may vary according to the type of analysis that is performed. However, we chose the intentionto-treat type of analysis to best inform nephrologists and patients at the time when decisions on future treatment are being made. We feel that there is very little data available to help this process. Changing to an as-treated analysis would be less useful for this purpose. Performing the as-treated analysis would focus on the effect of dialytic treatment, which was not the primary purpose of the study. Using an as-treated analysis, where the start point of the study is at eGFR of 15 mL/min, could be flawed, as those patients needing dialysis would generally have survived longer. Patients who choose dialysis do have a better survival. We are not claiming that this is necessarily due to dialysis treatment. Indeed, as Misra et al. point out, patients who chose dialysis may not have started treatment, either because of death or not requiring dialysis in the study period. We therefore speculate that many factors affect the decision to choose dialysis, including patient's wishes and advice from physicians. These factors are not readily identified from the medical records. However, the result is that the two groups of patients identified at the time of the dialysis decision have different survival, some of this difference possibly being attributable to dialysis.
